REducing Blood Pressure Variability in Essential Hypertension With RAmipril vErsus Nifedipine GITS Trial
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 168 participants.
Also called NCT02499822
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 168 participants
- Registry
-
NCT02499822
-
- Other papers using this trial's data
- A Randomized Controlled Trial on the Efficacy and Safety of a Calcium-Channel Blocker and an Angiotensin-Converting Enzyme Inhibitor in Chinese and European Patients with Hypertension
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China, Greece, Italy
- Registry status
- Completed
Technical summary
Registry record NCT02499822. Randomized; single masking; primary purpose treatment. Start 2015-10 (registry gives no type); primary completion 2020-07-03 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- REducing Blood Pressure Variability in Essential Hypertension With RAmipril vErsus Nifedipine GITS Trial
- Acronym
- REVERENT
- Condition
- Hypertension
- Condition
- High Blood Pressure Variability
- Intervention (Drug)
- Nifedipine GITS
- Intervention (Drug)
- Ramipril
- Lead sponsor
- Istituto Auxologico Italiano
- Collaborator
- Bayer
Record details
- Record id
cardio:ct-nct02499822- Content hash
3c3abc25504778dcd2bada7c57850e6cddcbfced77dde17be21d8f2ce14c71ec